Cytochrome P4502C9 activity in end-stage renal disease

被引：73

作者：

Dreisbach, AW ^{[1
]}

Japa, S

Gebrekal, AB

Mowry, SE

Lertora, JJL

Kamath, BL

Rettie, AE

机构：

[1] Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Clin Pharmacol, New Orleans, LA 70118 USA

[2] Tulane Univ, Sch Med, Dept Pathol, Sect Nephrol & Clin Pharmacol, New Orleans, LA 70118 USA

[3] Tulane Univ, Sch Med, Dept Pharmacol, Sect Nephrol & Clin Pharmacol, New Orleans, LA 70118 USA

[4] Xavier Univ, Coll Pharm, Dept Pharmacokinet, New Orleans, LA 70125 USA

[5] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 05期

关键词：

D O I：

10.1016/S0009-9236(03)00015-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：475 / 477

页数：3

共 7 条

[1] EFFECT OF RENAL-FAILURE ON DRUG-METABOLISM BY THE LIVER [J].

ELSTON, AC ;

BAYLISS, MK ;

PARK, GR .

BRITISH JOURNAL OF ANAESTHESIA, 1993, 71 (02) :282-290

[2] Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype [J].

Henne, KR ;

Gaedigk, A ;

Gupta, G ;

Leeder, JS ;

Rettie, AE .

JOURNAL OF CHROMATOGRAPHY B, 1998, 710 (1-2) :143-148

[3]

Leblond F, 2001, J AM SOC NEPHROL, V12, P326, DOI 10.1681/ASN.V122326

[4] Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data [J].

Lee, CR ;

Goldstein, JA ;

Pieper, JA .

PHARMACOGENETICS, 2002, 12 (03) :251-263

[5] Genetic association between sensitivity to warfarin and expression of CYP2C9*3 [J].

Steward, DJ ;

Haining, RL ;

Henne, KR ;

Davis, G ;

Rushmore, TH ;

Trager, WF ;

Rettie, AE .

PHARMACOGENETICS, 1997, 7 (05) :361-367

[6]

Tanaka E, 1998, J CLIN PHARM THER, V23, P247

[7]

Trager WF, 2000, METABOLIC DRUG INTER, P403

← 1 →